RxDoctor Payments Data

Laura Santoro, MD

Family Medicine · Marquette, MINPI 1568800480

Payments from drug & device makers

$2,367in general payments, 2019–2025

Across 143 payments — averaging $16.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$412
  • Merck$306
  • AstraZeneca$263
  • Amgen$143
  • Pfizer$138
  • Novo Nordisk$137
  • plus $966 from 20 others

What the payments were for

  • Food & beverage$2,365100%
  • Education$10%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,367 in reported general payments places this provider in the 80th percentile of 3,945 family medicine providers in Michigan.

See all family medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$37,727
Medicare patients
112
Services billed
405

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban52$57,906
JanuviaSitagliptin Phosphate42$55,401
JardianceEmpagliflozin31$41,576
OzempicSemaglutide26$33,029
TrulicityDulaglutide24$30,460
Trelegy ElliptaFluticasone/Umeclidin/Vilanter35$29,976
RybelsusSemaglutide19$23,089
BelsomraSuvorexant22$9,345
Advair HfaFluticasone Propion/Salmeterol18$8,356
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog13$8,143
Lantus SolostarInsulin Glargine,hum.Rec.Anlog49$7,095
JanumetSitagliptin Phos/Metformin Hcl12$6,751
Stiolto RespimatTiotropium Br/Olodaterol Hcl11$4,757
SymbicortBudesonide/Formoterol Fumarate18$4,104
Atorvastatin Calcium304$3,422

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia, Belsomra, Janumet$306$71,49876 claims
PfizerEliquis$138$57,90652 claims
Novo NordiskOzempic, Rybelsus$137$56,11745 claims
Boehringer IngelheimJardiance, Stiolto Respimat$124$46,33342 claims
Lilly USA, LLCTrulicity$29$30,46024 claims
GSKTrelegy Ellipta$132$29,97635 claims
AstraZenecaSymbicort$263$4,10418 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,945 family medicine providers in Michigan.

Other family medicine in Marquette

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →